griseofulvin and Fetal-Death

Multiple congenital malformations occurred in kittens of three cats treated orally at weekly intervals with 500-1000 mg of the antifungal drug griseofulin. Malformations of the brain included exencephaly, malformed prosencephalon, caudal displacement, and hydrocephalus. Skeletal malformations included cranium bifidium, spina bifida (C1 through C4, and sacral), abnormal atlantooccipital articulation, cleft palate, absence of maxillae, and lack of tail vertebrae. Cyclopia and anophthalmia with absence of optic nerves and rudimentary optic tracts were also observed. Atresia ani, atresia coli, lack of atrioventricular valves in the heart, and absence of external nares and soft palate were other abnormalities present.

Topics: Abnormalities, Drug-Induced; Animals; Anophthalmos; Brain; Cat Diseases; Cats; Cleft Palate; Eye; Eye Abnormalities; Female; Fetal Death; Griseofulvin; Microsporum; Optic Chiasm; Optic Nerve; Orbit; Pregnancy; Spinal Dysraphism; Tinea

Griseofulvin, a fungistatic agent, was administered in oral doses of 125 to 1500 milligrams per kilogramn per day to pregnant rats during organogenesis. Evaluation of the offspring from dams treated with the largest doses, 63 and 75 times a therapeutic dose in man, indicated decreased survival rates and a syndrome of malformations.

Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Administration, Oral; Animals; Birth Weight; Bone and Bones; Female; Fertility; Fetal Death; Griseofulvin; Male; Pregnancy; Rats; Spermatogenesis

Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Anophthalmos; Brain; Female; Fetal Death; Genitalia; Griseofulvin; Hydrocephalus; Pregnancy; Pregnancy, Animal; Rats; Tail; Time Factors